Oral exemestane 25 mg/day for 2–3 years of adjuvant therapy was generally more effective than 5 years of continuous adjuvant tamoxifen in the treatment of postmenopausal women with early-stage estrogen receptor-positive/unknown receptor status breast in a large well-designed [ citation needed ] trial. Preliminary data from the open-label TEAM trial comparing exemestane with tamoxifen indicated in 2009 that exemestane 25 mg/day is also effective in the primary adjuvant treatment of early-stage breast cancer in postmenopausal women. 
Results wise, users should expect extreme strength increases and weight gain in a relatively short 2-4 week period. Weight gain upwards of 20lbs in 4 weeks is not unheard of with this incredibly potent compound. Although subcutaneous water gain would be minimal, intramuscular water retention should be expected. This is due to inhibition of 11b-hydroxylase and build-up of mineralcorticoids which encourage salt and water retention within the muscles. The most obvious physical effects will be improved vascularity, aggressive muscular pumps, and oily skin.
While methyldrostanolone can stack well with most other steroids, it should never be stacked with another methylated (17aa) steroid.